Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19-Reference-Cited by-同舟云学术

Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19

Published:2023-10-04 Issue:10 Volume:6 Page:e2336854
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Mateo-Urdiales Alberto¹,Sacco Chiara¹²,Petrone Daniele¹,Bella Antonino¹,Riccardo Flavia¹,Del Manso Martina¹,Bressi Marco¹,Siddu Andrea³,Brusaferro Silvio⁴,Palamara Anna Teresa¹,Rezza Giovanni³,Pezzotti Patrizio¹,Fabiani Massimo¹,Boros Stefano⁵,D'Ancona Fortunato (Paolo)⁵,Di Benedetto Corrado⁵,Filia Antonietta⁵,Rota Maria Cristina⁵,Tallon Marco⁵,Vescio Maria Fenicia⁵,Petrucci Antonia⁵,La Bianca Michele⁵,Mignuoli Anna Domenica⁵,Buono Pietro⁵,Massimiliani Erika⁵,Barbone Fabio⁵,Vario Francesco⁵,Sticchi Camilla⁵,Cereda Danilo⁵,Pompili Marco⁵,Sforza Francesco⁵,Bertoli Pierpaolo⁵,Benetollo Pier Paolo⁵,Pasqualini Chiara⁵,Cisceglia Lucia⁵,Palmas Maria Antonietta⁵,Addario Sebastiano Pollina⁵,Balocchini Emanuela⁵,Tosti Anna⁵,Ruffier Mauro⁵,Da Re Filippo⁵,Battilomo Serena⁵,Proietti Valeria⁵,Odio Camillo⁵,Recine Michele⁵,Ruberto Innocenza⁵,Ascione Salvatore⁵,Bisogno Massimo⁵,Miserendino Gandolfo⁵,Navacchia Massimiliano⁵,Del Frate Beatrice⁵,Cau Emanuela⁵,Baiocchi Diego⁵,Fusco Danilo⁵,Gallo Domenico⁵,Marchetti Maria Rosa⁵,Conforti Diego⁵,Trentini Carlo⁵,Ruggeri Antonino⁵,Ladalardo Concetta⁵,Albano Nehludoff⁵,Corona Marco⁵,Lombardi Paolo⁵,Iacono Massimo⁵,Angori Paolo Bruno⁵,Belardinelli Andrea⁵,Solfiti Milena⁵,Fioraso Stefano⁵,Poma Chiara⁵,Raccanello Nadia⁵,

Affiliation:

1. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

2. European Programme for Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden

3. General Directorate of Prevention, Ministero della Salute, Rome, Italy

4. Office of the President, Istituto Superiore di Sanità, Rome, Italy

5. for the Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry

Abstract

ImportanceProtein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults in late 2021, but evidence on its estimated effectiveness in a general population is lacking.ObjectiveTo estimate vaccine effectiveness of a primary cycle with NVX-CoV2373 against SARS-CoV-2 infection and symptomatic COVID-19.Design, Setting, and ParticipantsRetrospective cohort study linking data from the national vaccination registry and the COVID-19 surveillance system in Italy during a period of Omicron predominance. All adults starting a primary vaccination with NVX-CoV2373 between February 28 and September 4, 2022, were included, with follow-up ending on September 25, 2022. Data were analyzed in February 2023.ExposuresPartial (1 dose only) vaccination and full vaccination (2 doses) with NVX-CoV-2373.Main Outcomes and MeasuresNotified SARS-CoV-2 infection and symptomatic COVID-19. Poisson regression models were used to estimate effectiveness against both outcomes. Adjusted estimated vaccine effectiveness was calculated as (1 − incidence rate ratio) × 100.ResultsThe study included 20 903 individuals who started the primary cycle during the study period. Median (IQR) age of participants was 52 (39-61) years, 10 794 (51.6%) were female, and 20 592 participants (98.5%) had no factors associated with risk for severe COVID-19. Adjusted estimated vaccine effectiveness against notified SARS-CoV-2 infection in those partially vaccinated with NVX-CoV2373 was 23% (95% CI, 13%-33%) and was 31% (95% CI, 22%-39%) in those fully vaccinated. Estimated vaccine effectiveness against symptomatic COVID-19 was 31% (95% CI, 16%-44%) in those partially vaccinated and 50% (95% CI, 40%-58%) in those fully vaccinated. Estimated effectiveness during the first 4 months after completion of the primary cycle decreased against SARS-CoV-2 infection but remained stable against symptomatic COVID-19.Conclusions and RelevanceThis cohort study found that, in an Omicron-dominant period, protein recombinant vaccine NVX-CoV2373 was associated with protection against SARS-CoV-2 infection and symptomatic COVID-19. The use of this vaccine could remain an important element in reducing the impact of the SARS-CoV-2 pandemic.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2810134/mateourdiales_2023_oi_231069_1695666277.35218.pdf

Reference29 articles.

1. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.;Andrews;N Engl J Med,2022

2. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine.;Heath;N Engl J Med,2021

3. Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.;Karbiener;npj Vaccines,2022

4. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.;Tarke;Cell,2022

5. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.;Hielscher;J Clin Virol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan;Emerging Infectious Diseases;2024-03